Who Paid My Doc
Julie Hong
Allergy & Immunology Clackamas, OR Medical Doctor
NPI 1609093871 CMS profile 978413
10180 Se Sunnyside Rd, Clackamas, OR 97015
General payments
$272
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Julie Hong of Clackamas, OR is reported in the CMS Open Payments database as having received $272 across 4 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 16th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $136 | 2 | |
| 2023 | General | $136 | 2 |
Beside peers
- Julie Hong
- Allergy & Immunology median
- Middle half of Allergy & Immunology
- National median
In program year 2025, general payments to Julie Hong were reported at $0. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.
Show as a table
| Year | Julie Hong | Allergy & Immunology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $594 | $163–$1,512 | $163 |
| 2020 | $0 | $426 | $106–$1,233 | $114 |
| 2021 | $0 | $638 | $157–$1,708 | $132 |
| 2022 | $0 | $790 | $205–$1,961 | $149 |
| 2023 | $136 | $852 | $220–$2,147 | $160 |
| 2024 | $136 | $865 | $203–$2,267 | $164 |
| 2025 | $0 | $1,140 | $272–$2,892 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 20 drugsPart D claims
1,446
Drug cost
$283,383
Branded share of claims
42.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Fasenra Pen Benralizumab | Brand | 17 | $91,357 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 76 | $57,292 | |
| Alvesco Ciclesonide | Brand | 189 | $37,379 | |
| Wixela Inhub Fluticasone Propion/Salmeterol | Brand | 98 | $28,946 | |
| Cromolyn Sodium | Generic | 15 | $12,543 | |
| Breyna Budesonide/Formoterol Fumarate | Brand | 49 | $12,467 | |
| Advair Hfa Fluticasone Propion/Salmeterol | Brand | 11 | $10,804 | |
| Epinephrine | Generic | 56 | $6,826 | |
| Ipratropium Bromide | Generic | 183 | $6,277 | |
| Azelastine Hcl | Generic | 225 | $5,596 |
The 10 drugs with the highest cost, of 20 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.
Records
4 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Allergy & Immunology in Oregon
Adam Williams
Allergy & Immunology · Bend, OR
Shyam Joshi
Allergy & Immunology · Portland, OR
Stephen Fritz
Allergy & Immunology · Happy Valley, OR
Anthony Montanaro
Allergy & Immunology · Portland, OR
Karen Anstey
Allergy & Immunology · Portland, OR
Michael Osborne
Allergy & Immunology · Portland, OR
Related records
Allergy & Immunology in Oregon
Practitioners in the same specialty and state, ranked by reported value.
All Allergy & Immunology
Everyone recorded under this specialty, nationwide.
Doctors in Oregon
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.